Becton, Dickinson and Company (BDX) FY2024 YTD Q3 P&L / Income Statement

Becton, Dickinson and Company (BDX) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2023-10-01 through 2024-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

14,741,000,000 US dollars

Cost of products sold

8,103,000,000 US dollars

Gross profit (calculated)

6,638,000,000 US dollars

Operating expenses (calculated)

4,863,000,000 US dollars

Operating Income

1,775,000,000 US dollars

Other income (expense), net (calculated)

negative 284,000,000 US dollars

Income Before Income Taxes

1,491,000,000 US dollars

Income tax provision

186,000,000 US dollars

Net Income

1,305,000,000 US dollars

Medical

7,237,000,000 US dollars

Life Sciences

3,852,000,000 US dollars

Interventional

3,720,000,000 US dollars

Integration, restructuring and transaction expense

288,000,000 US dollars

Research and development expense

888,000,000 US dollars

Selling and administrative expense

3,601,000,000 US dollars

Other operating expense (income), net

86,000,000 US dollars

Revenue before reconciliation (calculated)

14,809,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Corporate, Non-Segment

negative 67,000,000 US dollars. Reported reconciliation to consolidated revenue.

Rounding (calculated)

negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.